An observational study in Pancreas Cancer, Pancreatic Cancer and Pancreas Neoplasm, sponsored by George Zogopoulos. Recruiting at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-04-17.
Sponsored by George Zogopoulos · Observational
Among 184 studies in Pancreatic Neoplasms with a site in Canada — 37 open to participants now, 60 under way, 9 of them phase 3. Pancreatic Neoplasms · Canada.
Among the 184 studies in Pancreatic Neoplasms with a site in Canada, this one is the 4th largest by planned enrollment of the 20 observational ones that give a count, is one of 8 that started in 2012, is one of 20 observational ones, reaches primary completion later than 1 of the 59 other live ones, and was the 119th registered.
3,896 studies on the registry are indexed under Pancreatic Neoplasms; 1,007 are open to participants now.
Browse Pancreatic Neoplasms studies →37 of the 184 studies in Pancreatic Neoplasms with a site in Canada are open now. Recruiting first, the newest first:
Bristol-Myers Squibb · Sites in Canada, United States, Belgium and 10 more countries
Ages 18+
Verastem, Inc. · Sites in Canada, United States, Australia and 1 more country
Ages 18+
University Health Network, Toronto · Sites in Canada
Ages 18+
Unity Health Toronto · Sites in Canada
Ages 18+
Incyte Corporation · Sites in Canada, United States, Australia and 19 more countries
Ages 18+
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 746 Pancreatic Neoplasms studies recruiting now, 479 (64%) set no upper age limit and 151 (20%) stop at 75 or younger; 40 take children under 18; 59 take healthy volunteers.
This study: 18 Years and older · all sexes.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
184 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 55 · Phase 2 71 · Phase 3 39 · Phase 4 1
First in 1998; this study’s year is marked. 8 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 2,000 is above the median of 200 across 740 observational studies indexed under Pancreatic Neoplasms.
Median enrollment 119 across the 161 interventional studies, 450 across the 20 observational. Of the 119 that completed or were terminated, 44 (37%) have results posted.
This tab as a report to print or save as PDF → With an account.
107 of 184 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with George Zogopoulos as lead sponsor.
George Zogopoulos has 1 study filed under Pancreatic Neoplasms — fewer than ten, so there is no comparison to draw.
20 of the studies in Pancreatic Neoplasms with a site in Canada that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05687123National Cancer Institute (NCI)Testing the Addition of Sunitinib Malate to Lutetium Lu 177 Dotatate (Lutathera) in Pancreatic Neuroendocrine Tumors | 2026-12-14 |
| NCT02912949Partner Therapeutics, Inc.A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy) | 2026-12-31 |
| NCT04276857University of SaskatchewanSystemic Therapy With a Loco-regional Treatment in Patients With Locally Advanced Pancreatic Cancer | 2026-12-31 |
| NCT05941507LigaChem Biosciences, Inc.A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors | 2027-01 |
| NCT03816358National Cancer Institute (NCI)Testing the Combination of Anetumab Ravtansine With Either Nivolumab, Nivolumab and Ipilimumab, or Gemcitabine and Nivolumab in Advanced Pancreatic Cancer | 2027-01-31 |
Add all 20 to your calendar (.ics) → With an account.
Among the 184 studies in Pancreatic Neoplasms with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The Quebec Pancreas Cancer Study is a prospective clinic-based study consisting of clinical, family history and epidemiologic data, with accompanying biospecimens, from patients diagnosed with either pancreas cancer, a related cancer or a related pre-cancerous condition, and their families.
The objectives of the QPCS are as follows:
Individuals diagnosed with pancreatic cancer or related cancer followed in a hospital in Quebec.
High-risk individuals with Familial Pancreatic Cancer or hereditary predisposition to pancreatic cancer with or without a family history of pancreatic cancer.
Healthy controls.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Individuals affected with pancreatic adenocarcinoma, with or without a family history of pancreatic adenocarcinoma.
Individuals affected with bile duct cancer, ampullary cancer, duodenal cancer or gallbladder cancer.
Individuals affected with pancreatic neoplasm, cyst or pre-cancerous lesion, with or without a family history of pancreatic adenocarcinoma.
Individuals at high lifetime risk of pancreatic adenocarcinoma due to familial pancreatic cancer or hereditary cancer predisposition.
Healthy individual at general population lifetime risk of pancreatic cancer and related cancers.
Knowledge and Tissue Bank
Create a knowledge and tissue bank for pancreatic cancer, related pre-cancerous lesions, and related cancers, including patient demographics, type of chemotherapy treatments, type of surgical procedures, other procedures, overall survival, progression-free survival, epidemiological risk factors, genetic factors and characteristics of tumour tissue.
Time frame: 10 years
Started Mar 2012 (actual). Primary completion is estimated for Jan 2025, 154 months after the start.
Of 318 non-industry observational studies under Pancreatic Neoplasms, half reached primary completion within 74 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 182. This study's planned 154 months is above that.
Counting every sponsor, half of 352 studies reached it within 60 months; a quarter within 34 and three quarters within 182.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.